Denali Therapeutics Inc. Restricted Cash and Cash Equivalents, Current
Denali Therapeutics Inc. (DNLI) had Restricted Cash and Cash Equivalents, Current of $0 as of 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue · last filed 2020-02-27
- 2019-12-31: Restricted Cash and Cash Equivalents, Current $0.00.
- 2019-09-30: Restricted Cash and Cash Equivalents, Current $0.00.
- 2018-12-31: Restricted Cash and Cash Equivalents, Current $0.00.
- 2018-09-30: Restricted Cash and Cash Equivalents, Current $0.00.
| Period end | Restricted Cash and Cash Equivalents, Current |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-27 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-06 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-27 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-06 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 |
| 2017-12-31 | $84.00K 10-K · filed 2020-02-27 |
| 2017-09-30 | $84.00K 10-Q · filed 2018-11-08 |
| 2017-06-30 | $84.00K 10-Q · filed 2018-08-09 |
| 2017-03-31 | $84.00K 10-Q · filed 2018-05-11 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |